<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04253275</url>
  </required_header>
  <id_info>
    <org_study_id>IBIS-CT (29BRC19.0268)</org_study_id>
    <nct_id>NCT04253275</nct_id>
  </id_info>
  <brief_title>Identification of Biomarkers in Ischemic Stroke - Clinical Trial</brief_title>
  <acronym>IBIS-CT</acronym>
  <official_title>Identification of Biomarkers in Ischemic Stroke - Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to determine RNA blood biomarker based on 9 genes already&#xD;
      identified in experimental studies, whose expression would be significantly increased in&#xD;
      patient with ischemic stroke compared to controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a monocentric study. It's a case-control study with case being first-ever ischemic&#xD;
      stroke and controls being healthy (stroke free) subject patients paired for age, sex and&#xD;
      cardiovascular risk or hemorrhagic stroke paired for age and sex.&#xD;
&#xD;
      Patients are followed for one year. Blood samples will be taken at inclusion, 12h, 24h, 48h,&#xD;
      7d, 3m and 1y. Microvesicles samples will be taken at inclusion, 7d and 3M.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Expression (measured in log2) of each 9 targeted genes identified less than 6 hours after inclusion</measure>
    <time_frame>6 hours after inclusion</time_frame>
    <description>Each targeted genes will be measured by quantitative reverse transcription Polymerase Chain Reaction (rt-PCR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RNA level expression across time according growth of infarction measured at inclusion and at 3 months</measure>
    <time_frame>inclusion and 3 months</time_frame>
    <description>Each targeted genes will be measured by quantitative rt-PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RNA level expression across time according Rankin scale at three months dichotomized in good (â‰¤ 2) and bad prognosis (&gt; 3).</measure>
    <time_frame>at 3 months</time_frame>
    <description>Each targeted genes will be measured by quantitative rt-PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Targeted RNA level expression according mechanism of ischemic stroke</measure>
    <time_frame>at 3 months</time_frame>
    <description>Each targeted RNA level expression of targeted genes will be measured by quantitative rt-PCR</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Stroke, Ischemic</condition>
  <condition>Stroke Hemorrhagic</condition>
  <arm_group>
    <arm_group_label>Ischemic stroke patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with ischemic stroke diagnosed on clinical presentation and cerebral imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hemorragic stroke patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with hemorragic stroke diagnosed on clinical presentation and cerebral imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stroke-free</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>Blood samples will be taken at inclusion, 12h, 24h, 48h, 7d, 3m and 1y for patients ; at inclusion, 3m and 1y for controls.&#xD;
Microvesicles samples will be taken at inclusion, 7d and 3M ; at inclusion and 3M for controls.</description>
    <arm_group_label>Ischemic stroke patients</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_label>hemorragic stroke patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI without injection</intervention_name>
    <description>MRI at inclusion for controls</description>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For ischemic stroke :&#xD;
&#xD;
          -  Age &gt; 18-year-old&#xD;
&#xD;
          -  Ischemic stroke diagnosed on clinical presentation and cerebral imaging (CT or MRI&#xD;
             imaging)&#xD;
&#xD;
          -  Inclusion inferior to 6 hours from stroke onset&#xD;
&#xD;
          -  Initial NIHSS score &gt; 0 at the time of clinical examination&#xD;
&#xD;
          -  Patients with multimodal imaging either through MRI or CT perfusion and supra-aortic&#xD;
             vessels and intra-cerebral vessels (Willis circle) imaging &lt;0&#xD;
&#xD;
          -  Procedure of signed consent in situation of emergency : consent of the patient if he&#xD;
             has the possibility to sign or his representative if he is present&#xD;
&#xD;
          -  For hemorragic stroke :&#xD;
&#xD;
          -  Age &gt; 18 year-old&#xD;
&#xD;
          -  Hemorrhagic stroke diagnosed on clinical presentation and cerebral imaging (CT or MRI&#xD;
             imaging)&#xD;
&#xD;
          -  Inclusion inferior to 6 hours from stroke onset&#xD;
&#xD;
          -  Initial NIHSS score &gt; 0 at the time of clinical examination&#xD;
&#xD;
          -  Hemorrhagic patients are paired for age and sex with ischemic patients&#xD;
&#xD;
          -  Procedure of signed consent in situation of emergency : consent of the patient if he&#xD;
             has the possibility to sign or his representative if he is present&#xD;
&#xD;
        For healthy controls :&#xD;
&#xD;
          -  Age &gt; 18 year-old&#xD;
&#xD;
          -  Stroke-free standardized questionnaire&#xD;
&#xD;
          -  Initial NIHSS score = 0&#xD;
&#xD;
          -  Rankin score = 0&#xD;
&#xD;
          -  High risk cardiovascular subjects&#xD;
&#xD;
          -  Controls are paired for age, sex and cardiovascular risk measured by a score (European&#xD;
             Heart Score) with ischemic patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not affiliated to social security&#xD;
&#xD;
          -  Patient under legal protection or deprived of liberty by a judicial or administrative&#xD;
             decision&#xD;
&#xD;
          -  Patient whose follow-up will be impossible&#xD;
&#xD;
          -  Prior stroke&#xD;
&#xD;
        GROUP FOR ISCHEMIC STROKE :&#xD;
&#xD;
        - Patients with TIA and a negative cerebral CT or MRI&#xD;
&#xD;
        GROUP FOR HEMORRAGIC STROKE :&#xD;
&#xD;
          -  Cerebral hemorrhage related to subarachnoid hemorrhage&#xD;
&#xD;
          -  Post-traumatic hemorrhage&#xD;
&#xD;
          -  Hemorrhagic transformation in patients with ischemic stroke&#xD;
&#xD;
        GROUP FOR HEALTHY CONTROLS :&#xD;
&#xD;
        - Contraindication MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serge TIMSIT, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>serge.timsit@chu-brest.fr</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Serge TIMSIT, Pr</last_name>
    <phone>298147349</phone>
    <phone_ext>+33</phone_ext>
    <email>serge.timsit@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serge TIMSIT, PU-PH</last_name>
      <email>serge.timsit@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Serge TIMSIT, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Hemorrhagic Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available after the publication of result and ending fifteen years following the last visit of the last patient</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

